KOSDAQBiotech & Pharma950220

NeoImmuneTech

₩1,450▼ 2.36%2026-11-18 close
Market Cap
₩49.6B
Turnover
₩90,462,106
Volume
60K
Shares out.
34.2M
PER
—
PBR
1.2×
EPS
-₩617
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Prices as of the 2026-11-18 close

01

Report overview

Revenue Rises and Losses Narrow, but Cash Outflows Persist

Q3 2026 revenue reached KRW 4.48 billion in the same quarter as the August NT-I7 licensing deal, and operating losses narrowed, but operating cash outflows and four consecutive years of losses remain.

  1. 1

    Q3 2026 revenue was KRW 4.48 billion, up from KRW 17.41 million in Q3 2025 (based on filed results).

  2. 2

    Operating loss narrowed from KRW 60.4 billion in 2022 to KRW 23.8 billion in 2025, but the company has posted losses for four consecutive years from 2022 to 2025.

  3. 3

    On August 19, 2026, the company signed an NT-I7 licensing deal with Tolerance Bio. The upfront payment is a 4% equity stake, and milestones total up to USD 260 million (about KRW 366.9 billion).

  4. 4

    Operating cash flow was KRW -23.6 billion in 2025, still negative, while the debt-to-equity ratio fell from 57.0% in 2024 to 38.6% in 2025.

  5. 5

    Because the last four quarters were net losses, the price-to-earnings ratio is not calculable, and the price-to-book ratio sits in a slight premium to net assets.

02

Business structure

NeoImmuneTech is a T-cell-based immunotherapy developer founded in 2014 in Rockville, Maryland.

Its lead pipeline asset is NT-I7 (efineptakin alfa), a long-acting interleukin-7 that expands T cells, which the company is testing in combination with immune checkpoint inhibitors for cancer and in infectious disease and thymic dysfunction indications.

In a February 2026 interview reported by the press, the acting CEO and CFO set 2026 as the year revenue becomes visible, shifting from R&D toward commercialization, and said partner acquisition for NT-I7 is the focus.

On August 19, 2026, the company disclosed a licensing agreement with US-based Tolerance Bio that transfers exclusive development and commercialization rights for NT-I7 in thymic dysfunction indications, including immune reconstitution in people living with HIV, covering North America, South America, Central America and Europe.

The upfront consideration is a 4% equity stake in the counterparty. Development and sales milestones total up to USD 260 million (about KRW 366.9 billion), and after commercialization the company is entitled to tiered royalties tied to net sales.

Major areas such as immuno-oncology are excluded from the deal and remain with the company. In May 2026 the company announced it had received a final US sales license from the State of Maryland for Endari, a treatment for sickle cell anemia.

The competitive-products section of the company's filings lists 14 institutions developing antibodies against the same target.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩17,409,820-₩4.3B−24577.2%
2025Q4₩36,235,128-₩5.7B−15603.0%
2026Q1₩500M-₩5.7B−1180.5%
2026Q2₩1.1B-₩3.8B−359.8%
2026Q3₩4.5B-₩3.7B−83.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩0-₩60.4B-₩62.7B—−49.5%16.9%
2023₩0-₩57.2B-₩54.9B—−70.5%20.9%
2024₩200M-₩39.4B-₩40.2B−23497.6%−105.8%57.0%
2025₩89,454,759-₩23.8B-₩30B−26596.6%−54.2%38.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-11

04

Earnings analysis

On a filed-results basis, annual revenue fell from KRW 168 million in 2024 to KRW 89.45 million in 2025, a 46.6% decline.

Operating loss was KRW 60.4 billion in 2022, KRW 57.2 billion in 2023, KRW 39.4 billion in 2024 and KRW 23.8 billion in 2025, so the loss has narrowed each year, and the company recorded losses in every year from 2022 to 2025.

Net loss attributable to controlling shareholders declined from KRW 62.7 billion in 2022 to KRW 30 billion in 2025, and net loss including non-controlling interests followed the same path. The operating margin was -23,497.6% in 2024 and -26,596.6% in 2025, figures that look extreme because revenue is so small.

Operating cash flow was KRW -44.9 billion in 2022 and KRW -23.6 billion in 2025, so the outflow shrank but remained negative. The debt-to-equity ratio fell from 57.0% in 2024 to 38.6% in 2025.

At year-end 2025, total equity was KRW 55.4 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 21.4 billion. Quarterly revenue rose from KRW 17.41 million in Q3 2025 to KRW 4.48 billion in Q3 2026, and Q3 2026 was up 323.5% from the prior quarter.

The August 19 licensing agreement falls within Q3 2026, but the breakdown of revenue should be checked in the notes to the periodic report.

Operating loss in Q3 2026 was KRW 3.75 billion, narrower than the prior quarter and the year-earlier quarter, and net loss attributable to controlling shareholders was KRW 3.81 billion.

Over the last four quarters, net loss attributable to controlling shareholders totaled KRW 21.1 billion, and no quarter in the filed window has reached a profit.

05

Industry analysis

In the immunotherapy field where the company operates, clinical trials that combine immune checkpoint inhibitors with T-cell-based treatments are the main trend. The company emphasizes that its IL-7 mechanism helps sustain T-cell function.

In early June 2026, the company presented results from a combination study with Immunocore, a global immuno-oncology company, as a poster at ASCO 2026.

The presented data included T-cell function being maintained under repeated antigen stimulation and increased expression of related genes in patient-derived immune cells. These findings come from analyses of patient samples and should not be read as proof of clinical efficacy.

The competitive-products section of the company's filings lists 14 institutions developing antibodies against the same target, which points to a broad field of competitors.

In terms of licensing, the Tolerance Bio deal targets a thymic-function indication in people living with HIV, which is distinct from the company's immuno-oncology strategy.

Acute radiation syndrome (ARS) treatments have a different development path, because the indication can be approved based on animal data rather than human trials. A position comparison with listed peers in biopharma should use the same yardsticks for pipeline stage, licensing terms and depth of clinical data.

06

Outlook

Because the company set 2026 as the year revenue becomes visible, the next checkpoints are whether the milestone and royalty terms of the licensing deal are realized.

In a February 2026 interview, the CFO said the convertible bond balance was about KRW 10 billion and that conversion into shares would have a debt-structure improvement effect.

In the same interview, the company said it had no additional fundraising plans for now, while it would consider strategic cooperation with institutional investors.

In May 2026 the company announced it had obtained the final US sales license for Endari, and it mentioned plans to strengthen marketing of the sickle cell treatment. The investigator-led CAR-T combination trial planned to enroll 6 to 12 patients, and three had been enrolled at the time of the May 2026 report.

For the ARS treatment, final data from a primate model study started in the US in 2023 were expected as early as the end of 2026, according to that report.

At the March 2026 annual general meeting, shareholders approved a share consolidation and articles amendments, and the number of common shares outstanding fell under a 5-to-1 consolidation. The stated purpose was to rationalize the float and support share-price stability.

The next checkpoint is therefore how revenue composition and operating cash flow change in the 2026 annual report.

07

Valuation

PER
—
PBR
1.2×
ROE
-38.8%
EPS
-₩617
BPS
₩1,343
Dividend per share
—

The price-to-book ratio sits in a slight premium to net assets. Because net losses attributable to controlling shareholders have continued over the last four quarters, the price-to-earnings ratio cannot be calculated.

Total equity of KRW 55.4 billion at year-end 2025 is entirely attributable to controlling shareholders, which makes a capital-based comparison more informative. Over the multi-year period, losses have narrowed, but there has been no year of profit from 2022 to 2025.

Licensing milestones depend on clinical development and sales achievements, so they are not fixed amounts already reflected in current equity. Valuation interpretation therefore centers on pipeline clinical results and whether the contract milestones are realized.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-11

08

Bull factors

Licensing deal opens a commercial route

The August 19, 2026 agreement with Tolerance Bio transfers exclusive development and commercialization rights for NT-I7 in thymic dysfunction indications. The upfront payment is a 4% equity stake, and milestones total up to USD 260 million (about KRW 366.9 billion).

After commercialization, royalties tied to net sales apply, and immuno-oncology remains with the company. The company described the deal as its first licensing since listing and as recognition of NT-I7's commercial potential in global markets.

Revenue scale up, losses narrowing

Annual revenue fell from KRW 168 million in 2024 to KRW 89.45 million in 2025, but quarterly revenue rose to KRW 483 million in Q1 2026, KRW 1.06 billion in Q2 and KRW 4.48 billion in Q3. Operating loss narrowed from KRW 3.8 billion in Q2 2026 to KRW 3.75 billion in Q3.

The start of a quarter-on-quarter revenue climb can be read as an early sign of a change in the profit structure.

Lower leverage and a stated balance-sheet plan

The debt-to-equity ratio fell from 57.0% in 2024 to 38.6% in 2025. Total equity of KRW 55.4 billion at year-end 2025 is entirely attributable to controlling shareholders, against total liabilities of KRW 21.4 billion.

In February 2026 the company said that converting the roughly KRW 10 billion convertible bond balance into shares would improve the balance sheet. In May 2026 a filing reported that CEO Kim Tae-kyung bought depositary receipts on the open market, bringing his stake to 0.08%.

09

Bear factors

Operating cash outflows continue

Operating cash flow was KRW -23.6 billion in 2025, down from KRW -44.9 billion in 2022, but still negative. Net loss attributable to controlling shareholders over the last four quarters totaled KRW 21.1 billion.

If the current pace of losses continues against KRW 55.4 billion in equity, the need for new funding could come back into focus, and this is the main bearish point.

Uncertainty in clinical progress

A May 2026 press report said that five and a half years after FDA approval of the clinical trial plan in October 2020, enrollment of 83 patients had not been completed. The company said the trial was voluntarily suspended because of personal circumstances of the lead investigator.

The same report described a shift from company-led trials toward investigator-led studies. Phase 2a objective response rate was reported at 4.1% under RECIST 1.1, so proof of efficacy remains an open task.

Conditional nature of deal income

Milestone payments depend on clinical development and sales achievements, so the full deal value is not fixed income. The upfront payment is an equity stake in the counterparty rather than cash.

Whether the Q3 revenue increase reflects the upfront or later milestones should be checked in the notes to the periodic report. Whether deal income recurs each quarter is hard to judge from filings so far.

10

Risk factors

Clinical and regulatory risk

Clinical results for NT-I7 have shown wide variation across indications and patient groups in past reports. The objective response rate in patients with liver metastasis was reported at 2.7%, a clear gap from the group without liver metastasis.

Shifting to investigator-led trials makes data quality and schedule control more important. For ARS, which can follow an animal-data approval path, the interpretation of final data will be central.

Funding and dilution risk

Operating cash flow was KRW -23.6 billion in 2025, against total equity of KRW 55.4 billion. In its February 2026 interview the company said it had no additional fundraising plans for now, but share-count increases from convertible bond conversion remain possible.

The 5-to-1 consolidation reduced the number of shares outstanding, but it does not by itself change the underlying business value.

Partner and contract dependence

The HIV-related indication licensed to Tolerance Bio depends on the partner's development capability and fundraising.

Major combination trials in immuno-oncology rely on checkpoint inhibitors supplied free of charge by global pharmaceutical companies, so changes in supply terms or partner strategy could affect trial timelines. Milestone realization depends on the partner's pace of development.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    This is the reference date for total equity, convertible bond balance and the direction of operating cash flow. The baseline figures for the 2026 annual report are set at this date.

  2. Late 2026 onward (based on press outlook)

    Whether final data from the primate model study for the ARS candidate are disclosed. These results are needed to judge the feasibility of the animal-data approval path.

  3. Late March 2027 (annual report filing deadline)

    Q4 and full-year 2026 results will be disclosed in the periodic report. Check the composition of the Q3 revenue increase, the amount of licensing revenue recognized, and the trend in operating cash flow.

12

Overall view

NeoImmuneTech's August 2026 NT-I7 licensing agreement falls within Q3 2026, when revenue rose to KRW 4.48 billion and operating loss narrowed to KRW 3.75 billion. However, operating cash flow was KRW -23.6 billion in 2025, and the company has recorded losses in every year from 2022 to 2025.

Total equity of KRW 55.4 billion and a debt-to-equity ratio of 38.6% provide some financial room, but the effect of the loss pace on the capital base remains a point to monitor. Milestones and royalties depend on clinical development and sales achievements, so they are not fixed income.

On valuation, the price-to-book ratio sits in a slight premium to net assets, and because the last four quarters were net losses, the price-to-earnings ratio is not calculable.

The next checkpoints are the annual revenue composition in the 2026 annual report, the trend in operating cash flow, and the final data from the ARS animal study.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. alphasquare.co.kr
  2. hankyung.com
  3. press9.kr
  4. digitaltoday.co.kr
  5. m.news.nate.com
  6. digitaltoday.co.kr
  7. jobkorea.co.kr
  8. m.news.nate.com
  9. g-enews.com
  10. edaily.co.kr
  11. pharm.edaily.co.kr
  12. edaily.co.kr
  13. edaily.co.kr
  14. etoday.co.kr
  15. edaily.co.kr
  16. goinsider.kr
  17. startupticker.ch

Report written 2026-11-12 · Data as of 2026-11-11

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis